Bayer Acquires Perfuse in $2.45 Billion Deal

Viridian Executive Discusses FDA Approval of New TED Therapy

An executive from Viridian discusses the FDA approval of Lumvoa for thyroid eye disease (TED); a biosimilar referencing Lucentis is relaunched in the US; and Lumibird introduces a wireless integrated laser-indirect-ophthalmoscope. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Ocular Updates Plans for Axpaxli NDA for Wet AMD

Ocular Therapeutix provides a key update on its NDA plans for wet AMD drug candidate Axpaxli; Thea US launches a first-of-its-kind eye gel for glaucoma; and there were several recent milestones reached in the clinical development of novel drugs for a variety of ocular conditions. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Tecnis PureSee IOL Fully Launched in the US

Johnson & Johnson expands the availability of its latest Tecnis lens; Bayer completes its acquisition of Perfuse Therapeutics, expanding its presence in ophthalmology; and ophthalmic leaders discuss how to navigate the current regulatory environment of the FDA. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Study Examines Semaglutide and Wet AMD Risk

An international study examines the link between a popular weight loss medication and wet AMD risk; Heidelberg receives FDA clearance for a Spectralis software upgrade; and Bausch + Lomb launches its latest over-the-counter dry eye relief product in the US. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Oculis Announces Phase 3 Results for DME Eye Drops

Oculis Releases phase 3 data for its investigational eye drop for DME; Rayner expands its surgical offerings with the launch of a new OVD; and a biosimilar referencing Eylea is launched in Europe. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]